HOOK Overview

Asset Sale Announcement: HOOKIPA Pharma Inc. has completed the sale of its HB-400 and certain HB-500 program assets to Gilead Sciences, with the transaction closing on October 30, 2025.

Program Details: The HB-400 program is in clinical development for hepatitis B treatment, while the HB-500 program is focused on human immunodeficiency virus (HIV) treatment, both developed in collaboration with Gilead.

Investor Communication: HOOKIPA emphasizes the importance of its investor relations website and other channels for disseminating material financial information to investors and the public.

Social Media Usage: The company encourages stakeholders to review information shared on social media, as it may contain material information relevant to investors and the public.

Delisting Announcement: HOOKIPA Pharma has announced its voluntary delisting from the Nasdaq Capital Market and plans to deregister its common stock, following an asset sale agreement with Gilead Sciences for key assets related to hepatitis B and HIV programs.

Future Plans: A special stockholder meeting is scheduled for July 29, 2025, to vote on the asset sale and potential company dissolution, with plans to file for dissolution in Delaware and begin liquidation proceedings upon approval.

Acquisition Announcement: HOOKIPA Pharma has announced that Gilead Sciences will acquire certain assets related to its antiviral programs for up to $10 million, focusing on treatments for Hepatitis B and HIV.

Payment Structure: The deal includes an initial payment of $3 million at closing, with potential additional payments of up to $7 million based on the completion of three phases, pending approval from HOOKIPA's stockholders.

Analyst Rating and Price Target: RBC Capital analyst Brian Abrahams has maintained a Hold rating on Hookipa Pharma with a price target of $2.00, while the company's shares closed at $1.41.

Company Financial Performance: Hookipa Pharma reported a quarterly revenue of $4.7 million and a GAAP net loss of $13.84 million for the quarter ending September 30, showing an improvement from last year's revenue of $6.87 million and a net loss of $19.07 million.

Development of HB-500: HOOKIPA Pharma, in collaboration with Gilead Sciences, is advancing the next-generation therapeutic vaccine HB-500 for HIV treatment, with enrollment completed for a Phase 1b clinical trial involving 30 participants, expected to conclude by H2 2025.

Vaccine Mechanism and Goals: HB-500 utilizes genetically engineered vectors to deliver HIV antigens aimed at inducing strong immunity, targeting over 80% of circulating HIV-1 variants, as part of a strategy for a potential functional cure for HIV.

Analyst Rating and Price Target: Hookipa Pharma received a Hold rating from Citi analyst Sean Lee, with a price target of $4.50, while its shares closed at $2.15.

Company Overview: Hookipa Pharma specializes in developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform, with products designed to enhance the immune response.